Nature Clinical Practice Rheumatology Nature Clinical Practice Rheumatology provides physicians with authoritative and timely interpretations of key developments in the field, translating the latest findings into clinical practice. http://www.nature.com/ncprheum/current_issue/ Nature Publishing Group en © 2008 Nature Publishing Group Nature Clinical Practice Rheumatology 1745-8382 1745-8390 © 2008 Nature Publishing Group permissions@nature.com Nature Clinical Practice Rheumatology http://www.nature.com/includes/rj_globnavimages/ncprheum_logo.gif http://www.nature.com/ncprheum/ The future of specialty care in the US http://dx.doi.org/10.1038/ncprheum0844 The future of specialty care in the US

Nature Clinical Practice Rheumatology 4, 333 (2008). doi:10.1038/ncprheum0844

Author: Richard A Cooper

]]> The future of specialty care in the US Richard A Cooper doi:10.1038/ncprheum0844 Nature Clinical Practice Rheumatology 4, 333 (2008) Nature Clinical Practice Rheumatology 4 7 Editorial 333 333 Combined MRI and SPECT assessment could aid diagnosis of NPSLE http://dx.doi.org/10.1038/ncprheum0786 Combined MRI and SPECT assessment could aid diagnosis of NPSLE

Nature Clinical Practice Rheumatology 4, 334 (2008). doi:10.1038/ncprheum0786

]]> Combined MRI and SPECT assessment could aid diagnosis of NPSLE doi:10.1038/ncprheum0786 Nature Clinical Practice Rheumatology 4, 334 (2008) Nature Clinical Practice Rheumatology 4 7 Research Highlights 334 335 Efficacy and safety of anti-TNF therapy for ankylosing spondylitis: long-term results http://dx.doi.org/10.1038/ncprheum0831 Efficacy and safety of anti-TNF therapy for ankylosing spondylitis: long-term results

Nature Clinical Practice Rheumatology 4, 334 (2008). doi:10.1038/ncprheum0831

]]> Efficacy and safety of anti-TNF therapy for ankylosing spondylitis: long-term results doi:10.1038/ncprheum0831 Nature Clinical Practice Rheumatology 4, 334 (2008) Nature Clinical Practice Rheumatology 4 7 Research Highlights 334 334 Intravenous ibandronate is an effective and well-tolerated treatment for osteoporosis http://dx.doi.org/10.1038/ncprheum0810 Intravenous ibandronate is an effective and well-tolerated treatment for osteoporosis

Nature Clinical Practice Rheumatology 4, 335 (2008). doi:10.1038/ncprheum0810

]]> Intravenous ibandronate is an effective and well-tolerated treatment for osteoporosis doi:10.1038/ncprheum0810 Nature Clinical Practice Rheumatology 4, 335 (2008) Nature Clinical Practice Rheumatology 4 7 Research Highlights 335 335 Possible role for complement inhibition in amelioration of arthritis http://dx.doi.org/10.1038/ncprheum0832 Possible role for complement inhibition in amelioration of arthritis

Nature Clinical Practice Rheumatology 4, 335 (2008). doi:10.1038/ncprheum0832

]]> Possible role for complement inhibition in amelioration of arthritis doi:10.1038/ncprheum0832 Nature Clinical Practice Rheumatology 4, 335 (2008) Nature Clinical Practice Rheumatology 4 7 Research Highlights 335 336 Novel CCL2 inhibitor alleviates established rat adjuvant-induced arthritis http://dx.doi.org/10.1038/ncprheum0833 Novel CCL2 inhibitor alleviates established rat adjuvant-induced arthritis

Nature Clinical Practice Rheumatology 4, 336 (2008). doi:10.1038/ncprheum0833

]]> Novel CCL2 inhibitor alleviates established rat adjuvant-induced arthritis doi:10.1038/ncprheum0833 Nature Clinical Practice Rheumatology 4, 336 (2008) Nature Clinical Practice Rheumatology 4 7 Research Highlights 336 336 MRI is more sensitive than radiography for the detection of RA wrist bone erosions http://dx.doi.org/10.1038/ncprheum0834 MRI is more sensitive than radiography for the detection of RA wrist bone erosions

Nature Clinical Practice Rheumatology 4, 336 (2008). doi:10.1038/ncprheum0834

]]> MRI is more sensitive than radiography for the detection of RA wrist bone erosions doi:10.1038/ncprheum0834 Nature Clinical Practice Rheumatology 4, 336 (2008) Nature Clinical Practice Rheumatology 4 7 Research Highlights 336 336 In Briefs http://dx.doi.org/10.1038/ncprheum0837 In Briefs

Nature Clinical Practice Rheumatology 4, 337 (2008). doi:10.1038/ncprheum0837

]]> In Briefs doi:10.1038/ncprheum0837 Nature Clinical Practice Rheumatology 4, 337 (2008) Nature Clinical Practice Rheumatology 4 7 Research Highlights 337 337 Is computer-assisted management necessary for patients with early rheumatoid arthritis? http://dx.doi.org/10.1038/ncprheum0817 Is computer-assisted management necessary for patients with early rheumatoid arthritis?

Nature Clinical Practice Rheumatology 4, 338 (2008). doi:10.1038/ncprheum0817

Authors: Daniel Aletaha & Josef Smolen

]]> Is computer-assisted management necessary for patients with early rheumatoid arthritis? Daniel Aletaha Josef Smolen doi:10.1038/ncprheum0817 Nature Clinical Practice Rheumatology 4, 338 (2008) 2008-05-20 Nature Clinical Practice Rheumatology 2008-05-20 4 7 Practice Point 338 339 Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis http://dx.doi.org/10.1038/ncprheum0822 Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis

Nature Clinical Practice Rheumatology 4, 340 (2008). doi:10.1038/ncprheum0822

Authors: Eamonn S Molloy & Carol A Langford

]]> Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis Eamonn S Molloy Carol A Langford doi:10.1038/ncprheum0822 Nature Clinical Practice Rheumatology 4, 340 (2008) 2008-05-27 Nature Clinical Practice Rheumatology 2008-05-27 4 7 Practice Point 340 341 Oral versus parenteral administration of methotrexate for the treatment of active RA http://dx.doi.org/10.1038/ncprheum0827 Oral versus parenteral administration of methotrexate for the treatment of active RA

Nature Clinical Practice Rheumatology 4, 342 (2008). doi:10.1038/ncprheum0827

Authors: Derrick J Todd & Michael E Weinblatt

]]> Oral versus parenteral administration of methotrexate for the treatment of active RA Derrick J Todd Michael E Weinblatt doi:10.1038/ncprheum0827 Nature Clinical Practice Rheumatology 4, 342 (2008) 2008-06-03 Nature Clinical Practice Rheumatology 2008-06-03 4 7 Practice Point 342 343 Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis? http://dx.doi.org/10.1038/ncprheum0819 Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis?

Nature Clinical Practice Rheumatology 4, 344 (2008). doi:10.1038/ncprheum0819

Authors: Tracy V Ting & Daniel J Lovell

]]> Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis? Tracy V Ting Daniel J Lovell doi:10.1038/ncprheum0819 Nature Clinical Practice Rheumatology 4, 344 (2008) 2008-05-20 Nature Clinical Practice Rheumatology 2008-05-20 4 7 Practice Point 344 345 What is the optimal treatment for patients with RA who fail to respond to monotherapy with methotrexate? http://dx.doi.org/10.1038/ncprheum0830 What is the optimal treatment for patients with RA who fail to respond to monotherapy with methotrexate?

Nature Clinical Practice Rheumatology 4, 346 (2008). doi:10.1038/ncprheum0830

Author: Boulos Haraoui

]]> What is the optimal treatment for patients with RA who fail to respond to monotherapy with methotrexate? Boulos Haraoui doi:10.1038/ncprheum0830 Nature Clinical Practice Rheumatology 4, 346 (2008) 2008-06-10 Nature Clinical Practice Rheumatology 2008-06-10 4 7 Practice Point 346 347 Are cannabinoids a new treatment option for pain in patients with fibromyalgia? http://dx.doi.org/10.1038/ncprheum0826 Are cannabinoids a new treatment option for pain in patients with fibromyalgia?

Nature Clinical Practice Rheumatology 4, 348 (2008). doi:10.1038/ncprheum0826

Authors: Roland Staud & Eubee B Koo

]]> Are cannabinoids a new treatment option for pain in patients with fibromyalgia? Roland Staud Eubee B Koo doi:10.1038/ncprheum0826 Nature Clinical Practice Rheumatology 4, 348 (2008) 2008-06-03 Nature Clinical Practice Rheumatology 2008-06-03 4 7 Clinical Advance 348 349 Is mizoribine a new therapeutic agent for Sjögren's syndrome? http://dx.doi.org/10.1038/ncprheum0823 Is mizoribine a new therapeutic agent for Sjögren's syndrome?

Nature Clinical Practice Rheumatology 4, 350 (2008). doi:10.1038/ncprheum0823

Authors: Haralampos M Moutsopoulos & George E Fragoulis

]]> Is mizoribine a new therapeutic agent for Sjögren's syndrome? Haralampos M Moutsopoulos George E Fragoulis doi:10.1038/ncprheum0823 Nature Clinical Practice Rheumatology 4, 350 (2008) 2008-05-27 Nature Clinical Practice Rheumatology 2008-05-27 4 7 Clinical Advance 350 351 Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus http://dx.doi.org/10.1038/ncprheum0815 Emerging data implicate a novel subset of CD4+ T cells, termed TH17 cells, in the pathogenesis of several autoimmune diseases. In this Viewpoint article, the authors discuss the role of TH17 cells in systemic lupus erythematosus and discuss their potential as a therapeutic target. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus

Nature Clinical Practice Rheumatology 4, 352 (2008). doi:10.1038/ncprheum0815

Authors: Hai Feng Pan, Dong Qing Ye & Xiang Pei Li

]]> Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus Hai Feng Pan Dong Qing Ye Xiang Pei Li doi:10.1038/ncprheum0815 Nature Clinical Practice Rheumatology 4, 352 (2008) 2008-05-13 Nature Clinical Practice Rheumatology 2008-05-13 4 7 Viewpoint 352 353 Why do we need noncommercial, investigator-initiated clinical trials? http://dx.doi.org/10.1038/ncprheum0814 Noncommercial, investigator-initiated trials are an essential part of clinical research. In this Viewpoint, the author describes the burden of current legislation on investigator-initiated trials and explores possible solutions. Why do we need noncommercial, investigator-initiated clinical trials?

Nature Clinical Practice Rheumatology 4, 354 (2008). doi:10.1038/ncprheum0814

Author: Alan Tyndall

]]> Why do we need noncommercial, investigator-initiated clinical trials? Alan Tyndall doi:10.1038/ncprheum0814 Nature Clinical Practice Rheumatology 4, 354 (2008) 2008-05-13 Nature Clinical Practice Rheumatology 2008-05-13 4 7 Viewpoint 354 355 Ethical issues in rheumatology clinical trials http://dx.doi.org/10.1038/ncprheum0829 Clinical trials in rheumatology, similar to other areas of research, are associated with a plethora of ethical issues. Relevant issues, depending on the type of trial (for example, early phase trials, prevention trials and postmarketing studies), are outlined in this article, along with issues related to the selection of control arms for clinical trials, the selection of relevant outcome measures and some of the challenges in obtaining informed consent. Ethical issues in rheumatology clinical trials

Nature Clinical Practice Rheumatology 4, 356 (2008). doi:10.1038/ncprheum0829

Authors: Jeremy Sugarman & Clifton O Bingham

]]> Ethical issues in rheumatology clinical trials Jeremy Sugarman Clifton O Bingham doi:10.1038/ncprheum0829 Nature Clinical Practice Rheumatology 4, 356 (2008) 2008-06-10 Nature Clinical Practice Rheumatology 2008-06-10 4 7 Review 356 363 Drug Insight: anti-tumor necrosis factor therapies for the vasculitic diseases http://dx.doi.org/10.1038/ncprheum0825 Biologic agents that target tumor necrosis factor represent an attractive approach to the treatment of vasculitic diseases, especially those associated with granuloma formation. Available data on the use of these agents for individual vasculitic diseases, and the potential to apply these data to the care of vasculitis patients in clinical practice are discussed in this Review. Drug Insight: anti-tumor necrosis factor therapies for the vasculitic diseases

Nature Clinical Practice Rheumatology 4, 364 (2008). doi:10.1038/ncprheum0825

Author: Carol A Langford

]]> Drug Insight: anti-tumor necrosis factor therapies for the vasculitic diseases Carol A Langford doi:10.1038/ncprheum0825 Nature Clinical Practice Rheumatology 4, 364 (2008) 2008-05-27 Nature Clinical Practice Rheumatology 2008-05-27 4 7 Review 364 370 Technology Insight: adult mesenchymal stem cells for osteoarthritis therapy http://dx.doi.org/10.1038/ncprheum0816 Although osteoarthritis is the most common form of joint disease, an effective treatment for this disease is lacking. In this Review, the authors outline the potential use of strategies based on mesenchymal stem cells, which can differentiate into cells of the chondrogenic lineage, in the regeneration and maintenance of damaged articular cartilage. Technology Insight: adult mesenchymal stem cells for osteoarthritis therapy

Nature Clinical Practice Rheumatology 4, 371 (2008). doi:10.1038/ncprheum0816

Authors: Ulrich Nöth, Andre F Steinert & Rocky S Tuan

]]> Technology Insight: adult mesenchymal stem cells for osteoarthritis therapy Ulrich Nöth Andre F Steinert Rocky S Tuan doi:10.1038/ncprheum0816 Nature Clinical Practice Rheumatology 4, 371 (2008) 2008-05-13 Nature Clinical Practice Rheumatology 2008-05-13 4 7 Review 371 380 Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus http://dx.doi.org/10.1038/ncprheum0818 Optic neuritis and myelitis can occur as manifestations of idiopathic demyelinating syndromes, as well as of systemic rheumatic syndromes. In this Case Study, Drs Birnbaum and Kerr present a patient with systemic lupus erythematosus and concomitant neuromyelitis optica (also known as Devic's syndrome), and discuss the distinguishing clinical and radiographic features critical for an accurate diagnosis. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus

Nature Clinical Practice Rheumatology 4, 381 (2008). doi:10.1038/ncprheum0818

Authors: Julius Birnbaum & Douglas Kerr

]]> Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus Julius Birnbaum Douglas Kerr doi:10.1038/ncprheum0818 Nature Clinical Practice Rheumatology 4, 381 (2008) 2008-05-20 Nature Clinical Practice Rheumatology 2008-05-20 4 7 Case Study 381 386 5-HT3 receptor antagonist for the treatment of tendinopathy http://dx.doi.org/10.1038/ncprheum0835 5-HT3 receptor antagonist for the treatment of tendinopathy

Nature Clinical Practice Rheumatology 4, E4 (2008). doi:10.1038/ncprheum0835

Authors: Kazem Mousavizadeh, Thomas Stratz, Wolfgang Mueller & Bernd L Fiebich

]]> 5-HT3 receptor antagonist for the treatment of tendinopathy Kazem Mousavizadeh Thomas Stratz Wolfgang Mueller Bernd L Fiebich doi:10.1038/ncprheum0835 Nature Clinical Practice Rheumatology 4, E4 (2008) Nature Clinical Practice Rheumatology 4 7 Article Response E4 E4 Clinical studies can be performed in an ethical manner http://dx.doi.org/10.1038/ncprheum0856 Clinical studies can be performed in an ethical manner

Nature Clinical Practice Rheumatology 4, E5 (2008). doi:10.1038/ncprheum0856

Author: Roy Fleischmann

]]> Clinical studies can be performed in an ethical manner Roy Fleischmann doi:10.1038/ncprheum0856 Nature Clinical Practice Rheumatology 4, E5 (2008) Nature Clinical Practice Rheumatology 4 7 Article Response E5 E5 Author response to “Clinical studies can be performed in an ethical manner” http://dx.doi.org/10.1038/ncprheum0857 Author response to “Clinical studies can be performed in an ethical manner”

Nature Clinical Practice Rheumatology 4, E6 (2008). doi:10.1038/ncprheum0857

Author: Paul L Romain

]]> Author response to “Clinical studies can be performed in an ethical manner” Paul L Romain doi:10.1038/ncprheum0857 Nature Clinical Practice Rheumatology 4, E6 (2008) Nature Clinical Practice Rheumatology 4 7 Article Response E6 E6